Sia Daneshmand, MD, reviews the results of the ENVISION trial, which evaluates chemoablation using a novel reverse gel formulation of mitomycin for patients with intermediate-risk bladder cancer. The trial achieved a 79% complete response rate at three months, with 80% of responders maintaining durability at one year. Dr. Daneshmand highlights the benefits of avoiding TURBT and the potential to reduce recurrent operating room visits, especially for older patients or those on anticoagulation. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
ANKTIVA plus BCG shows a 71% CR rate and up to 54 months of durable response in patients with BCG-unresponsive NMIBC-CIS.
Sequential chemotherapy has been increasingly used as a 1st-line treatment option for NMIBC due to the ongoing BCG shortage.
UGN-102 could become the first FDA-approved therapy for low-grade intermediate-risk non-muscle invasive bladder cancer.
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
Advertisement
Latest News
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
ANKTIVA plus BCG shows a 71% CR rate and up to 54 months of durable response in patients with BCG-unresponsive NMIBC-CIS.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.